953 / 1266
Study Objectives
•
Determine the recommended pediatric phase
2 dose (<18 years)
–
Maximum tolerated dose, or if not seen
–
Similar steady-state systemic exposure to adults
(AUC, 4000–5500 ng
h/mL)
•
Assess dabrafenib safety and efficacy in
pediatric population
107